Senior Director, Technical Operations

OXB is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has more than 30 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. At OXB, our people are at the heart of everything we do. We’re on a mission to enable life-changing therapies to reach patients around the world—and we’re looking for passionate individuals who embody our core values every day: Responsible, Responsive, Resilient, and Respectful. Following the expansion of our US footprint with the acquisition of a new commercial-scale viral vector facility in Durham, North Carolina we have some new opportunities to join us. We are recruiting a Sr Director, Technical Operations to join the Durham Leadership Team. Reporting directly into the Durham Site Head, this role will provide strategic and operational oversight for Manufacturing, MSAT, and Engineering, ensuring the reliable, compliant, and efficient delivery of clinical and commercial gene therapy programs. Partnering closely with the Bedford Process Development team, colleagues across the OXB network, and site leadership, this role will drive operational excellence, strengthen site capabilities, and enable future growth while delivering high-quality viral vector manufacturing solutions that improve patient lives. Your responsibilities in this role would be:

• Provide strategic leadership across Manufacturing, MSAT, and Engineering, ensuring technical operations are aligned with business objectives and optimized to support pilot, clinical, and commercial manufacturing activities.
• Lead, develop, and empower a high-performing technical operations organisation, fostering a culture of safety, quality, accountability, collaboration, and continuous improvement.
• Build and scale manufacturing capabilities through effective capacity planning, resource allocation, workforce development, and infrastructure investment to support current operations and future business growth.
• Ensure reliable, compliant, and efficient GMP operations by establishing robust manufacturing and engineering systems, maintaining regulatory compliance, and driving effective technical troubleshooting and operational problem-solving.
• Partner closely with Client Project Management, Technical Excellence, Process Development, Quality, Program Management, and Supply Chain teams to enable successful process transfers, manufacturing readiness, and delivery of client commitments.
• Drive operational excellence and business performance through lean methodologies, performance management, budget oversight, infrastructure optimisation, and strategic initiatives that improve productivity, efficiency, and cost effectiveness.

We are looking for:

• Bachelor’s degree in Engineering, Life Sciences, Manufacturing, Business, or related field required; advanced degree preferred.
• 15+ years progressive experience in biopharmaceutical manufacturing or technical operations leadership.
• 5+ years leading leaders (Director-level or equivalent leadership teams).
• Significant experience operating within clinical and commercial cGMP manufacturing environments, ideally within gene therapy, viral vectors, cell therapy, biologics, or other advanced therapy modalities.
• Proven success leading multi-functional technical operations organisations, including manufacturing and engineering functions, within highly regulated FDA and EMA environments.
• Deep understanding of GMP manufacturing operations, technical operations infrastructure, engineering systems, and manufacturing support functions, with experience supporting site growth, scale-up, or operational transformation.
• Demonstrated ability to drive strategic planning, operational excellence, continuous improvement, and manufacturing performance through effective leadership, decision-making, and risk management.
• Strong commercial and financial acumen, including budget ownership, resource planning, and cost management, combined with excellent stakeholder management and communication skills

This role does not offer sponsorship for work authorization. External applicants must be eligible to work in the United States. About Us: OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Why Join Us?

• 💸 Competitive total reward packages
• 🧘 Wellbeing programs that support your mental and physical health
• 🚀 Career development opportunities to help you grow and thrive
• 🤝 Supportive, inclusive, and collaborative culture
• 🧪 State-of-the-art labs and manufacturing facilities
• 🌍 A company that lives its values: Responsible, Responsive, Resilient, Respect

We want you to feel inspired every day. At OXB, we’re future-focused and growing fast. We succeed together—through passion, commitment, and teamwork. Ready to Make a Difference? Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.